Meeting
2023 ASCO Annual Meeting
Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label.
Authors
Jihong Zong
Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Jihong Zong , Xiaolong Jiao , Lucy Pan , Sarah Castelo , Chelsey Campbell , Barb Lennert , Amanda Bruno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6611)
DOI
10.1200/JCO.2023.41.16_suppl.6611
Abstract #
6611
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals.
First Author: Celine Yeh
Poster
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
First Author: Anezka Zemankova
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu
Poster
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
First Author: Ademola Samuel Ojo